Campbell Newman Asset Management 13F: Adds $21M to TMO Stake

Campbell Newman Asset Management dramatically expanded its investment in Thermo Fisher Scientific Inc. TMO, lifting its holdings by 1,708.1% during the quarter. According to a Form 13F filing with the SEC on October 22, 2026, the fund purchased an additional 30,933 shares to finish the period with 32,744 shares. The total value of the position stood at $22,103,837 as of the filing date. Thermo Fisher closed at $676.54 on the day of the filing.

TMO Thermo Fisher Scientific Inc.

$676.54 ▲ +14.50% year to date

1M 3M YTD

Daily close · Oct 22, 2026

What Changed in Campbell Newman Asset Management's Thermo Fisher Position

The fund previously held just 1,811 shares of the healthcare giant. By adding 30,933 shares, Campbell Newman turned its modest holding into a much larger position worth over $22.1 million. The filing reflects portfolio activity during the quarter, captured in the October disclosure.

Other Institutional Activity in Thermo Fisher

Other large institutional investors also adjusted their positions in the company around the same time. Franklin Resources, Inc. grew its holdings by 458,515 shares, ending the period with 7,271,514 shares worth about $4,919,469,921.

Thermo Fisher Scientific Inc. Stock Up 1.0%

Thermo Fisher shares recently traded around $694.02 as of October 23, 2026, putting the stock up about 2.6% since the filing date. The stock sits below its 52-week high of $705.79 and well above its 52-week low of $435.27. Shares are also trading above both their 50-day moving average of $641.93 and their 200-day moving average of $548.71.

Recent Earnings

Thermo Fisher reported trailing-twelve-month revenue of $47,351,001,088 with earnings of $18.96 per share. The company generated a net profit margin of 14.9% and a return on equity of 13.4%. Its year-over-year revenue growth stood at 9.1%. The company's next earnings report is scheduled for January 28, 2027.

Dividend

The company pays an annual dividend rate of $1.88 per share, which translates to a dividend yield of 0.27%. This payout is backed by a dividend payout ratio of 9.7% of earnings.

Insider Buying and Selling at Thermo Fisher Scientific Inc.

Company insiders completed several transactions in August 2026. On August 19, 2026, officer Lisa P Britt sold 11,440 shares at an average price of $613.12 for a total value of $7,014,093. Chief Executive Officer Marc N Casper sold 20,000 shares on August 21, 2026, valued at $12,561,823, and later sold 275 shares on August 24, 2026, worth $172,439. President Gianluca Pettiti sold 4,133 shares on August 31, 2026, at an average price of $614.38 for a total value of $2,539,233.

Analysts Set New Price Targets

Wall Street firms updated their views on the stock on October 22, 2026. On October 22, 2026, Barclays maintained its Overweight rating and raised its price target to $775.0 from $750.0. On the same day, RBC Capital maintained a Sector Perform rating and lifted its price target from $580.0 to $730.0. TD Cowen maintained a Buy rating on October 22, 2026, while raising its target to $810.0 from $760.0. Stifel maintained a Buy rating and increased its target to $775.0 from $650.0 on October 22, 2026. Baird maintained an Outperform rating on October 22, 2026, pushing its target to $756.0 from $723.0. The stock carries a consensus strong buy rating with a mean price target of $706.69 across 26 analyst opinions.

About Thermo Fisher

Headquartered in Waltham, Massachusetts, Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services around the world. The company operates through four main segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services, supporting research and clinical needs globally with roughly 125,000 employees.

Bottom Line

Investors will look toward Thermo Fisher's next earnings report on January 28, 2027, for further insight into revenue growth and profit margins. Future institutional filings will show whether funds like Campbell Newman maintain their expanded positions.